Journals / Turkish Journal of Pediatrics / 2018 / Cilt: 60 - Sayı: 5

An extreme entity in differential diagnosis of musculoskeletal involvement-fibrodysplasia ossificans progressiva: a case based review

Pages
593–597
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we present a young case of fibrodysplasiaossificans progressiva to remind the typical signs and symptoms of the diseaseto all clinicians caring for children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fibrodysplasia ossificans progressiva is one of the most devastating disorderof mankind characterized by progressive heterotopic ossification.
📊
Key Findings & Data:Apart fromhallux valgus, other symptoms start to develop in the first decade of life.The initial symptoms are tumefactive lesions on the back that gives animpression of benign or malignant tumoral lesion.
💡
Conclusion & Impact:Herein, we present a young case of fibrodysplasiaossificans progressiva to remind the typical signs and symptoms of the diseaseto all clinicians caring for children.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fibrodysplasia ossificans progressiva is one of the most devastating disorderof mankind characterized by progressive heterotopic ossification. Apart fromhallux valgus, other symptoms start to develop in the first decade of life.The initial symptoms are tumefactive lesions on the back that gives animpression of benign or malignant tumoral lesion. It may cause restrictedmotion of the neck and shoulders and magnetic resonance imaging of thelesions may be reported as myositis or myofasciitis and these children maybe referred to rheumatologists. Currently there is no definitive treatment ofthe disease but the most important issue in these patients is “primum nonnocere”, because any invasive procedure could potentially trigger a flare andheterotopic calcification. Herein, we present a young case of fibrodysplasiaossificans progressiva to remind the typical signs and symptoms of the diseaseto all clinicians caring for children.

🔖

Cite This Article

Keskindemirci, G., Çakan, M., Aktay-Ayaz, N., Karadağ, Ş. G. (2022). An extreme entity in differential diagnosis of musculoskeletal involvement-fibrodysplasia ossificans progressiva: a case based review. Turkish Journal of Pediatrics, Cilt: 60 - Sayı: 5, 593–597. https://ajindex.com/articles/613131

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: Diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev 2013; 10 (Suppl 2): 437-448
  2. Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008; 121: e1295-e1300
  3. Rider LG, Lindsey CB, Miller FW. Juvenile Dermatomyositis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR (eds). Textbook of Pediatric Rheumatology (7th ed). Philadelphia: Elsevier, 2016: 351-383
  4. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005; 116: e654-e661
  5. Kaplan FS, Kobori JA, Orellana C, et al. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients. Am J Med Genet A 2015; 167A: 2265-2271
  6. Kaplan FS. The skeleton in the closet. Gene 2013; 528:7-11
  7. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: Clinical and genetic aspects. Orphanet J Rare Dis 2011; 6: 80
  8. Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): A comprehensive global assessment. J Bone Miner Res 2016; 31: 650-656
  9. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006; 38: 525-527
  10. Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009; 30: 379-390
  11. Kaplan FS, Shore EM, Pignolo RJ; The International Clinical Consortium on Fibrodysplasia Ossificans Progressiva. The medical management of fibrodysplasia ossificans progressiva: Current treatment considerations. Clin Proc Intl Clin Consort FOP 2011; 4: 1-100
  12. Kaplan FS, Pignolo RJ, Shore EM. From mysteries to medicines: Drug development for fibrodysplasia ossificans progressive. Expert Opin Orphan Drugs 2013; 1: 637-649
  13. Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2010; 92: 686-691
  14. Önal M, Bajin MD, Yılmaz T. Fibrodysplasia ossificans progressiva: A case report. Turk J Pediatr 2014; 56: 561-564
  15. Topçu